Literature DB >> 16879293

Alexithymia in Parkinson's disease is related to severity of depressive symptoms.

A Costa1, A Peppe, G A Carlesimo, P Pasqualetti, C Caltagirone.   

Abstract

The authors investigated the possible relationship between depression and alexithymia in a population of hospitalized patients suffering from Parkinson's disease (PD). Fifty-eight PD patients without dementia participated in the study. Alexithymia was screened using the 20 item version of the Toronto Alexithymia Scale (TAS 20). Depression was diagnosed using a Structured Clinical Interview (SCID I) for DSM-IV. Severity of depression was evaluated with the Beck Depression Inventory (BDI). The prevalence of Alexithymia was about 21%. PD patients with major depression were significantly more alexithymic (TAS 20 average score = 61.4) than PD patients without depression (TAS 20 average score = 47.4) and, also, tended to be more alexithymic than PD patients with minor depression (MiD; TAS 20 average score =50.6), whereas no difference was found between PD patients with MiD and PD patients without depression. Moreover, high scores obtained on the BDI were found to strongly predict high level of alexithymia in these patients. These results extend to a cohort of PD patients previous data from the literature evidencing a strong association between alexithymia and severity of depressive symptoms.

Entities:  

Mesh:

Year:  2006        PMID: 16879293     DOI: 10.1111/j.1468-1331.2006.01216.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  12 in total

1.  Alexithymia, depression, and cognition in patients with Parkinson's disease.

Authors:  Gulay Kenangil; Mehmet Demir; Esma Tur; Fusun Domac
Journal:  Acta Neurol Belg       Date:  2021-01-16       Impact factor: 2.396

2.  The association between motor subtypes and alexithymia in de novo Parkinson's disease.

Authors:  Michele Poletti; Daniela Frosini; Cristina Pagni; Claudio Lucetti; Paolo Del Dotto; Gloria Tognoni; Roberto Ceravolo; Ubaldo Bonuccelli
Journal:  J Neurol       Date:  2010-12-25       Impact factor: 4.849

3.  Evaluation of alexithymia and depression in severe obese patients not affected by eating disorders.

Authors:  A Da Ros; P Vinai; N Gentile; G Forza; S Cardetti
Journal:  Eat Weight Disord       Date:  2011-03       Impact factor: 4.652

4.  Mixed emotions: the contribution of alexithymia to the emotional symptoms of autism.

Authors:  G Bird; R Cook
Journal:  Transl Psychiatry       Date:  2013-07-23       Impact factor: 6.222

5.  Emotion processing in Parkinson's disease: a three-level study on recognition, representation, and regulation.

Authors:  Ivan Enrici; Mauro Adenzato; Rita B Ardito; Antonia Mitkova; Marco Cavallo; Maurizio Zibetti; Leonardo Lopiano; Lorys Castelli
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240

Review 6.  Psychiatric aspects of Parkinson's disease.

Authors:  Sandeep Grover; Mansi Somaiya; Santhosh Kumar; Ajit Avasthi
Journal:  J Neurosci Rural Pract       Date:  2015-01

Review 7.  Cognitive, Emotional, and Auto-Activation Dimensions of Apathy in Parkinson's Disease.

Authors:  Jonathan Del-Monte; Sophie Bayard; Pierluigi Graziani; Marie C Gély-Nargeot
Journal:  Front Behav Neurosci       Date:  2017-11-21       Impact factor: 3.558

8.  Multiple sclerosis decreases explicit counterfactual processing and risk taking in decision making.

Authors:  Samanta Simioni; Myriam Schluep; Nadège Bault; Giorgio Coricelli; Joerg Kleeberg; Renaud A Du Pasquier; Markus Gschwind; Patrik Vuilleumier; Jean-Marie Annoni
Journal:  PLoS One       Date:  2012-12-05       Impact factor: 3.240

9.  Investigating emotions in Parkinson's disease: what we know and what we still don't know.

Authors:  Igor Sotgiu; Maria L Rusconi
Journal:  Front Psychol       Date:  2013-06-10

10.  Alexithymia and apathy in Parkinson's disease: neurocognitive correlates.

Authors:  Yelena Bogdanova; Alice Cronin-Golomb
Journal:  Behav Neurol       Date:  2013-01-01       Impact factor: 3.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.